• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

病例报告：低剂量白细胞介素-2：一种治疗由PD-1/PD-L1抑制剂引起的以毛囊周围水疱为主的大疱性类天疱疮的方法。

Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor.

作者信息

Zhang Yingyue, Cao Xianwei, Tong Jianbo

机构信息

Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Institute of Dermatology, Jiangxi Academy of Clinical Medical Sciences, Nanchang, China.

出版信息

Front Immunol. 2024 Dec 10;15:1496413. doi: 10.3389/fimmu.2024.1496413. eCollection 2024.

DOI:10.3389/fimmu.2024.1496413
PMID:39720733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11666436/
Abstract

OBJECTIVES

This study aimed to evaluate the efficacy of low-dose interleukin (IL-2) treatment for bullous pemphigoid (BP) caused by anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors.

METHODS

Low-dose IL-2 treatment was standardized for BP. The Bullous Pemphigoid Disease Area Index (BPDAI), 5D-Itch Scale (5D-IS), and Dermatology Life Quality Index (DLQI) were recorded before and after treatment, and hexachromatic lymphocytes, regulatory T cells (Treg cells), and cytokines were measured.

RESULTS

A significant decline in the BPDAI score, 5D-IS, and DLQI score was observed following treatment. The count of B-cells, CD4+ T-cells, CD8+ T-cells, Treg cells, and the levels of cytokines (IL-4, -8, and -10) were significantly downregulated in comparison to baseline measurements.

CONCLUSION

Low-dose IL-2 could be an effective therapeutic choice for treating BP caused by PD-1/PD-L1 inhibitors.

摘要

目的

本研究旨在评估低剂量白细胞介素（IL-2）治疗抗程序性细胞死亡蛋白1/配体1（PD-1/PD-L1）抑制剂所致大疱性类天疱疮（BP）的疗效。

方法

对BP患者的低剂量IL-2治疗进行标准化。记录治疗前后的大疱性类天疱疮疾病面积指数（BPDAI）、5D瘙痒量表（5D-IS）和皮肤病生活质量指数（DLQI），并检测六染色淋巴细胞、调节性T细胞（Treg细胞）和细胞因子。

结果

治疗后BPDAI评分、5D-IS和DLQI评分显著下降。与基线测量相比，B细胞、CD4+T细胞、CD8+T细胞、Treg细胞计数及细胞因子（IL-4、-8和-10）水平均显著下调。

结论

低剂量IL-2可能是治疗PD-1/PD-L1抑制剂所致BP的有效治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e843/11666436/0cc0d6926d9c/fimmu-15-1496413-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e843/11666436/400d7a1a6033/fimmu-15-1496413-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e843/11666436/60fe1d5716fd/fimmu-15-1496413-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e843/11666436/0cc0d6926d9c/fimmu-15-1496413-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e843/11666436/400d7a1a6033/fimmu-15-1496413-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e843/11666436/60fe1d5716fd/fimmu-15-1496413-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e843/11666436/0cc0d6926d9c/fimmu-15-1496413-g003.jpg

相似文献

1
Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor.病例报告：低剂量白细胞介素-2：一种治疗由PD-1/PD-L1抑制剂引起的以毛囊周围水疱为主的大疱性类天疱疮的方法。
Front Immunol. 2024 Dec 10;15:1496413. doi: 10.3389/fimmu.2024.1496413. eCollection 2024.
2
A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.一例纳武利尤单抗诱导的大疱性类天疱疮：程序性细胞死亡蛋白 1/程序性死亡配体 1 抑制剂相关皮肤毒性的综述及诊断与管理建议。
Oncologist. 2018 Oct;23(10):1119-1126. doi: 10.1634/theoncologist.2018-0128. Epub 2018 Jul 17.
3
Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.大疱性类天疱疮和二肽基肽酶-4 抑制剂相关大疱性类天疱疮中的调节性 T 细胞亚群。
J Dermatol Sci. 2020 Oct;100(1):23-30. doi: 10.1016/j.jdermsci.2020.08.004. Epub 2020 Aug 15.
4
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病：一项回顾性分析，评估了临床和组织病理学特征、频率以及对癌症治疗的影响。
J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.
5
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.PD-1 和 PD-L1 抑制剂相关大疱性类天疱疮的研究综述。
Int J Dermatol. 2018 Jun;57(6):664-669. doi: 10.1111/ijd.13984. Epub 2018 Apr 6.
6
Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial.低剂量白细胞介素 2 治疗中重度大疱性类天疱疮的疗效和安全性：一项单中心对照试验。
J Am Acad Dermatol. 2024 Dec;91(6):1113-1117. doi: 10.1016/j.jaad.2024.08.033. Epub 2024 Aug 23.
7
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.靶向 PD-1 和 PD-L1 的免疫检查点抑制剂相关的自身免疫性大疱性皮肤病。
Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.
8
Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study.程序性死亡受体-1和程序性死亡配体-1检查点抑制相关的大疱性类天疱疮：一项倾向匹配的回顾性队列研究。
Br J Dermatol. 2024 Jul 16;191(2):299-300. doi: 10.1093/bjd/ljae172.
9
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.循环调节性 T 细胞可预测接受 PD-1/PD-L1 抑制剂治疗的肺癌患者的疗效和非典型反应。
Cancer Immunol Immunother. 2022 Mar;71(3):579-588. doi: 10.1007/s00262-021-03018-y. Epub 2021 Jul 18.
10
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.癌症患者接受免疫检查点抑制剂治疗与大疱性类天疱疮的关联：一项系统评价。
JAMA Dermatol. 2022 Aug 1;158(8):933-941. doi: 10.1001/jamadermatol.2022.1624.

本文引用的文献

1
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.癌症患者接受免疫检查点抑制剂治疗与大疱性类天疱疮的关联：一项系统评价。
JAMA Dermatol. 2022 Aug 1;158(8):933-941. doi: 10.1001/jamadermatol.2022.1624.
2
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：ASCO 指南更新。
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.
3
Low-dose interleukin-2: A potential treatment for pemphigus vulgaris.
低剂量白细胞介素-2：寻常型天疱疮的一种潜在治疗方法。
Autoimmun Rev. 2021 Oct;20(10):102906. doi: 10.1016/j.autrev.2021.102906. Epub 2021 Jul 15.
4
The role of T cells in pemphigus vulgaris and bullous pemphigoid.T 细胞在寻常型天疱疮和大疱性类天疱疮中的作用。
Autoimmun Rev. 2020 Nov;19(11):102661. doi: 10.1016/j.autrev.2020.102661. Epub 2020 Sep 14.
5
Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis.低剂量白细胞介素 2：类风湿关节炎的生物学和治疗前景。
Autoimmun Rev. 2020 Oct;19(10):102645. doi: 10.1016/j.autrev.2020.102645. Epub 2020 Aug 13.
6
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.免疫检查点抑制剂治疗的皮肤毒性：组织病理学特征综述。
J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. doi: 10.1016/j.jaad.2020.04.105. Epub 2020 Apr 29.
7
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.肝细胞癌中免疫检查点抑制剂毒性的诊断和管理。
J Hepatol. 2020 Feb;72(2):320-341. doi: 10.1016/j.jhep.2019.10.021.
8
Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2.皮肌炎/多肌炎患者循环调节性T细胞绝对数量减少，低剂量白细胞介素-2可使其恢复。
Ann Rheum Dis. 2021 Aug;80(8):e130. doi: 10.1136/annrheumdis-2019-216246. Epub 2019 Oct 14.
9
Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.二肽基肽酶-4抑制剂相关大疱性类天疱疮中的表位扩展现象
Br J Dermatol. 2019 May;180(5):1267-1268. doi: 10.1111/bjd.17690. Epub 2019 Feb 25.
10
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.在一项单臂开放临床试验中，低剂量白细胞介素-2 对 11 种自身免疫性疾病的免疫和临床疗效。
Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24.